Centre Hospitalier Lyon Sud — Clinical Trial Site

12 Registered trials

5 Currently recruiting

Organisation

Centre Hospitalier Lyon Sud

Location

Pierre Bénite, France

Identifier

ORL-000004539

Address

165 Chemin du Grand Revoyet, 69495 Pierre Bénite, 69495, France

Departments

gastro enterology
GI
Haematology
Hematology
n/a
Pneumology
Radiotherapy
Service d'Hématologie Clinique
Service de chirurgie Gale
Service de Médecine Interne- Centre de référence Mucoviscidose- Bâtiment 1A –2ème étage
Service Hématologie Clinique

Clinical trials at this site (12)

Search interface

Reduced post-transplant cyclophosphamide dose in patients undergoing haploidentical hematopoietic stem cell transplantation for hematologica… Pending

2024-519986-23-00 The study will involve adult women and men from 16 Fren 5
WIthdrawal of DUpilumab in Severe Asthma : a randomised non-inferiority-controlled trial Recruiting

2024-516789-13-00 Severe asthma 6 2025-12-15
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting

2024-516109-21-00 Polycythaemia Vera (PV) 5 2024-12-09
FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING I… Recruiting

2024-514107-34-00 BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANC 4 2024-07-18
Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse Recruiting

2024-517390-24-00 Ovarian epithelial cancer : intraperitoneal resectable 5 2011-04-26
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended

2024-515637-14-00 Cystic Fibrosis 5 2022-11-08
MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex… Ended

2023-509208-14-00 MULTIPLE MYELOMA 5 2021-09-28
A Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With MM Who Are Refractory to at Least One PI, One IMiD and One Ant… Ended

2023-504479-25-00 Multiple myeloma 4 2021-08-20
Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended

2024-513972-16-00 - Resected tumors of sinuses or salivary glands - Non-o 5 2017-01-30
Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended

2023-508820-37-00 Cytomegalovirus Infection (CMV) 5 2022-02-03
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended

2024-516201-23-00 Lung Cancer, NSCLC 4 2019-08-26